Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?

Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?

Although around 80% of endometrial cancers are diagnosed at early stages and present with a 5-year survival rate exceeding 95%, patients with advanced and recurrent disease show a poor prognosis and low response rates to standard chemotherapy. In the era of targeted therapy, the great advances in th...

Full description

Bibliographic Details
Main Authors: Lucia Musacchio, Serena Maria Boccia, Giuseppe Caruso, Giusi Santangelo, Margherita Fischetti, Federica Tomao, Giorgia Perniola, Innocenza Palaia, Ludovico Muzii, Sandro Pignata, Pierluigi Benedetti Panici, Violante Di Donato
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Journal of Clinical Medicine
Subjects:
endometrial cancer
immune checkpoint inhibitors
targeted therapy
Online Access:https://www.mdpi.com/2077-0383/9/6/1721

Internet

https://www.mdpi.com/2077-0383/9/6/1721

Similar Items